Shockwave Medical, Inc. Stock Price, News & Analysis

Shockwave Medical reported a robust Q3 2021 with revenue reaching $65.2 million, a significant rise of 233% compared to $19.6 million in Q3 2020. This growth is attributed to the launch of their Shockwave C2 product and increased adoption of their technologies. The gross profit also improved to $54.2 million, yielding a gross margin of 83%. Operating expenses rose to $51.4 million, primarily due to salesforce expansion. The company forecasts full-year revenue to be between $227 million and $228 million, signaling continued growth.

Shockwave Medical (NASDAQ: SWAV) presented new findings at the TCT annual symposium, confirming the efficacy of coronary Intravascular Lithotripsy (IVL) in treating calcified cardiovascular diseases. The one-year outcomes from the Disrupt CAD III study showed low rates of major adverse cardiovascular events (13.8%) and target lesion failure (11.9%). Analysis revealed consistent stent performance across different calcium morphologies and similar safety outcomes between men and women. The data supports IVL's role as a transformative treatment option in cardiovascular interventions.

Shockwave Medical (SWAV) announced that the Centers for Medicare & Medicaid Services (CMS) has increased payment rates for above the knee (ATK) peripheral intravascular lithotripsy (IVL) procedures. Effective January 1, 2022, these changes will enhance reimbursement for three specific HCPCS codes used for various IVL procedures in lower extremity arteries. This adjustment aims to improve patient access to IVL technology and acknowledges the resources required to perform these procedures.

Shockwave Medical (NASDAQ: SWAV) announced positive interim results from the Disrupt PAD III Observational Study, validating the effectiveness of Intravascular Lithotripsy (IVL) in treating complex calcified lesions. Analyzing data from 752 patients, the study revealed that IVL safely modifies superficial and deep calcium, achieving a final residual stenosis of 24%. Notably, complications are minimal, with only 0.9% and 0.1% of patients experiencing final dissections and perforations, respectively. The study enhances the evidence base for treating patients with severe calcification, completing enrollment in June 2021 with 1,373 patients.

Shockwave Medical, Inc. (Nasdaq: SWAV) will report its third quarter financial results on November 8, 2021, after market close. A conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET, which investors can access by calling (866) 795-9106 domestically or (470) 495-9173 internationally, using conference ID: 9166273. Shockwave Medical focuses on innovative treatment for calcified cardiovascular disease through its Intravascular Lithotripsy (IVL) technology, aiming to improve patient outcomes.

Shockwave Medical (NASDAQ: SWAV) will participate in two virtual investor conferences. The 2021 Virtual Wells Fargo Healthcare Conference features a fireside chat on September 9, 2021, at 9:20 a.m. Eastern Time. Additionally, the Morgan Stanley 19th Annual Global Healthcare Conference follows with a fireside chat on September 13, 2021, at 2:45 p.m. Eastern Time. Interested parties can access live and archived webcasts via the company’s website.

Shockwave is dedicated to revolutionizing calcified cardiovascular disease treatment through its innovative Intravascular Lithotripsy (IVL) technology.

Shockwave Medical (SWAV) reported significant financial growth for Q2 2021, with revenue reaching $55.9 million, a 444% increase from $10.3 million in Q2 2020. This growth was driven by the launch of the Shockwave C2 device and increased adoption of its products. Gross profit surged to $46 million with a gross margin of 82%. Despite a net loss of $0.4 million, an improvement from $18.1 million in the previous year, the company projects a full-year revenue guidance of $218 million to $223 million, reflecting a growth forecast of 222% to 229%.